Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $339,829.86 in Stock

Posted by Stanley Muller on Sep 6th, 2026

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) insider Elizabeth Lin sold 4,601 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $73.86, for a total value of $339,829.86. Following the sale, the insider owned 18,707 shares in the company, valued at $1,381,699.02. This represents a 19.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $80.00, for a total value of $127,200.00.
On Wednesday, September 2nd, Elizabeth Lin sold 5,387 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total value of $430,960.00.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $90.78 on Friday. The business’s 50-day moving average price is $66.01 and its 200-day moving average price is $65.93. Tarsus Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $91.53. The firm has a market capitalization of $3.98 billion, a price-to-earnings ratio of -83.28 and a beta of 0.54. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The firm had revenue of $173.91 million for the quarter, compared to the consensus estimate of $169.65 million. Equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -2.06 EPS for the current year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC boosted its position in Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after acquiring an additional 291 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Tarsus Pharmaceuticals by 367.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock worth $50,000 after acquiring an additional 558 shares in the last quarter. Comerica Bank lifted its stake in shares of Tarsus Pharmaceuticals by 470.0% in the 4th quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after purchasing an additional 705 shares during the period. Truvestments Capital LLC lifted its stake in shares of Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after purchasing an additional 468 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its position in shares of Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on TARS. Mizuho decreased their price target on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Finally, Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Three analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.50.

Check Out Our Latest Research Report on Tarsus Pharmaceuticals

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

Positive Sentiment: Tarsus completed its acquisition of Alkeus, obtaining worldwide rights to gildeuretinol (ALK-001), an investigational once-daily oral treatment for Stargardt disease. The rare inherited eye disease has no FDA-approved therapy and may affect up to 86,000 people in the United States. Tarsus completes Alkeus acquisition
Positive Sentiment: ALK-001 is being evaluated in the global NORTHSTAR Phase 3 trial and has received FDA Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations. The regulatory designations and potential to address a significant unmet need strengthen Tarsus’ pipeline, although topline trial data are not expected until 2029. Alkeus acquisition adds Phase 3 program
Positive Sentiment: Newly published TEASE-1 results showed that daily gildeuretinol significantly reduced the growth rate of retinal atrophic lesions versus an untreated group and was well tolerated, with no reported delays in dark adaptation or night blindness. TEASE-1 study results
Neutral Sentiment: The acquisition expands Tarsus beyond its commercial XDEMVY business and supports management’s strategy of building a broader eye-care company. However, the transaction’s financial terms and the ultimate commercial value of ALK-001 were not detailed in the reports.
Negative Sentiment: Insider Elizabeth Lin reported multiple sales totaling approximately $898,000 across September 1–2 under a pre-arranged Rule 10b5-1 trading plan. While such planned transactions may not reflect current management views, the sales add a modest cautionary signal for investors.

About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.